Previous 10 | Next 10 |
2023-05-03 07:25:22 ET Deciphera Pharmaceuticals press release ( NASDAQ: DCPH ): Q1 GAAP EPS of -$0.60 misses by $0.01 . Revenue of $33.45M (+14.6% Y/Y) misses by $2.05M . For further details see: Deciphera Pharmaceuticals GAAP EPS of -$0.60 misses by $0....
– First Quarter 2023 Total Revenue of $33.4 Million; Net Product Revenue for QINLOCK® Increased 15% to $33.2 Million Compared to First Quarter 2022 – – Enrollment Complete in the MOTION Pivotal Phase 3 Study of Vimseltinib; Top-line Results Expected in the Fourth...
2023-05-02 13:12:36 ET Deciphera Pharmaceuticals ( NASDAQ: DCPH ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is -$0.60 (+25.0% Y/Y) and the consensus Revenue Estimate is $35.5M (+21.6% Y/Y). Over t...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3,...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the St...
2023-03-29 11:49:16 ET The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this event. For further details see: Deciphera Pharmaceuticals, Inc.(DCPH) Investor Presentation - Slideshow
2023-03-25 08:00:00 ET Summary Last year, Deciphera Pharmaceuticals, Inc. was almost destroyed by a trial failure. This year, Deciphera Pharmaceuticals has demonstrated huge benefit in a subpopulation, and also progressed the rest of its pipeline. The cash position is decent, ...
2023-03-18 05:21:53 ET Summary Deciphera has a strong portfolio of investigational kinase inhibitors, including ripretinib, vimseltinib, and DCC-3116, that have demonstrated encouraging preliminary efficacy and safety data in treating various types of cancer. The company has compl...
2023-03-16 17:25:25 ET Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) had risen 13.4% for the week as of late Thursday afternoon, according to data provided by S&P Global Market Intelligence . The company, which focuses on oncology therapies, announced that the Food ...
– Top-line Results Expected in the Fourth Quarter of 2023 – – Phase 1/2 Data Demonstrated Vimseltinib’s Best-in-Class Potential for the Treatment of TGCT – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on d...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...